Vimarsana
Biggest News Aggregation in the World

Page 2 - Breast Program News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Breast Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Breast Program Today - Breaking & Trending Today

'We can not afford the status quo': What systems aren't talking about enough - Vimarsana News

'We can not afford the status quo': What systems aren't talking about enough

Leaders in healthcare discuss the overlooked aspects of improving the system, including value strategies, personalized wellness, collaboration, and more

Neoadjuvant Chemotherapy Could Help Patients With Breast Cancer Skip Regional Nodal Irradiation - Vimarsana News

Neoadjuvant Chemotherapy Could Help Patients With Breast Cancer Skip Regional Nodal Irradiation

No established standard of care currently exists after spread to the lymph nodes.

A Journey Across the Atlantic Leads to a Path in Surgical Oncology - Vimarsana News

A Journey Across the Atlantic Leads to a Path in Surgical Oncology

A planned 5-year trip in the United States coupled with a thirst for knowledge turned into a lifetime of surgical oncology accomplishments for Eleftherios “Terry” Mamounas, MD, MPH.

When to Skip Regional Nodal Radiation in Breast Cancer - Vimarsana News

When to Skip Regional Nodal Radiation in Breast Cancer

When neoadjuvant chemotherapy turns positive lymph nodes negative, 5-year survival outcomes are the same whether patients have regional nodal irradiation or not.

Neoadjuvant chemotherapy can eliminate need for regional nodal irradiation in breast cancer - Vimarsana News

Neoadjuvant chemotherapy can eliminate need for regional nodal irradiation in breast cancer

For patients whose breast cancer converted from lymph node-positive to lymph node-negative disease after neoadjuvant chemotherapy, skipping adjuvant regional nodal irradiation (RNI) did not increase the risk of disease recurrence or death five years after surgery, according to results from the NRG Oncology/NSABP B-51/RTOG 1304 clinical trial presented at the San Antonio Breast Cancer Symposium, held December 5-9, 2023.